That's the one paused, soon resumed and the best part, hardly cost CHM any $$$$
(1) CHM 0201 Combination Clinical Trials CHM 0201 + Vactosertib Phase 1B Clinical Trial at Case Western Reserve University In January 2023, the first patient was treated in a Phase 1B clinical trial studying CHM 0201 in combination with IL-2 and Vactosertib, an oral TGF-β receptor. The trial was designed to study 12 patients with colorectal cancer or Acute Myeloid Leukemia and is the first study to explore NK cells in combination with Vactosertib. Although the trial was paused in early 2024 due to a lack of staff resources at Case Western, the company expects the clinical trial to be resumed shortly and anticipates completion of the clinical trial in 2024
CHM Price at posting:
2.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)